ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
LEIDEN, The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) announced today the closing of its initial public offering of 8,625,000 ordinary shares at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,125,000 additional ordinary shares. The aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $102 million. The company's ordinary shares were approved for listing on the NASDAQ Global Market and began trading under the symbol "PRQR" on September 18, 2014.
Leerink Partners and Deutsche Bank Securities acted as joint book-running managers for the offering. JMP Securities acted as lead manager, and H.C. Wainwright & Co., LLC acted as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at Syndicate@Leerink.com, or by phone at 800-808-7525 ext. 6142; or from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by email at prospectus.cpdg@db.com, or by phone at (800) 503-4611.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ProQR
We are an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis. Utilizing our unique, proprietary RNA repair technologies, we believe we will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation. We believe that this is a unique approach that offers advantages compared with small molecule, gene therapy and other therapeutic strategies.
ProQR:
Daniel de Boer
Chief Executive Officer
T: +31 85 489 49 32
info@proqr-tx.com
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
T: +49 172 861 8540
gschweitzer@macbiocom.com
